S764
Clinical - Lung
ESTRO 2026
PTV. SBRT was administered using VMAT. The prescribed dose was 30 Gy with at least 95% of the PTV covered by 100% isodose. To ensure proper coverage of the target pre-fraction 4D-CBCT and a second intra-fraction CBCT were performed. Toxicity was assessed by Common Terminology Criteria for Adverse Events version 5 (CTCAE v5). Survival was estimated using the Kaplan-Meier method. Results: Mean age was 73.4 years (range 49–88) Sex: 41 men, 9 women. Mean Charlson Score: 2.75 (46% ≥ 3). Primary or suspected new primary: 76% of cases, oligometastatic: 24%. Confirmatory biopsy NSCLC: 12%; no biopsy: 88%. Mean tumor diameter: 13.6 mm (range 7-28). Mean ITV: 3.2 cc (range 0.6-8.4); mean PTV: 13.2 cc (range 4,5-27,3). Mean dose: 29.9 Gy (range 26-30). Dmax: 37.01 Gy (range 32.78-43.15); Dmean: 33.03 Gy (range 30.04-32.8); D95: 29.6 Gy (range 26.3-31.6); D99: 29.4 Gy (range 25.8-30.9). 22% received systemic therapy. Pattern of failure: 1 local (in-field), 3 isolated regional, 4 isolated distant, both regional-distant in 3, 5 deaths. Mean actuarial overall survival (OS) was 33.6 months (95% CI: 29–37.9) median not reached. Two-year actuarial survival end points: OS: 83.7%. Local control: 95.8%. Disease-free survival (DFS): 77.2%. Regional DFS: 88.8%. Distant DFS: 83,2%. Toxicity: Grade 3 pneumonitis, confined to the irradiated lobe, in 2 patients (4%). Conclusion: The excellent oncological results, combined with the associated logistical advantages, encourage the use of SF-SBRT in this group of patients. Although the data of this series is not yet mature, growing evidence supports this approach. References: 1- Tas KT et al. From protocol to practice: long-Term outcomes of single-Fraction stereotactic body radiotherapy for primary non-Small cell lung cancer. doi: 10.1007/s00066-025-02462-42- O'Keeffe et al. A strategy to reduce fraction number in peripheral lung stereotacticablative body radiotherapy. doi: 10.1016/j.phro.2023.1004293- Kang et al. Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung. doi: 10.1016/j.lungcan.2022.06.014 Keywords: Single Fraction SBRT, elderly, comorbidities
Conclusion: This pilot study suggests that both [18F]-FDG and [18F]-FAPI-PET parameters may have prognostic value in advanced lung cancer, with FDG SUVmax independently predicting locoregional progression. These findings support its use in risk stratification and dose-escalation strategies, though larger prospective studies are needed to clarify FAPI´s role in this population. Keywords: FAPI PET/CT Digital Poster 724 Improving access and outcomes: Single-fraction SBRT for lung tumors in a dispersed aging population Joaquín Cabrera Rodríguez, María Medina Cobacho, Patricia Ruiz Leal, Camila Fernández Alcalá, Esther Agudo Rey, Carmen Corral Fernández Radiation Oncology, Hospital Universitario de Badajoz, Badajoz, Spain Purpose/Objective: SBRT is typically indicated in early lung tumors for inoperable patients due to age or comorbidities. Reducing the number of sessions is crucial to minimise hospital visits and improve quality of life. Our university hospital is the only institution offering all modalities of stereotactic radiotherapy at Badajoz, Spain’s largest province (21,766 km ² ), which exceeds the size of countries like Slovenia or Wales and serves a sparsely populated (30.6 inhabitants/km ² ), predominantly rural and ageing population (over 18% aged 65+) As Single-fraction SBRT (SF-SBRT) has proven effective and safe for treating primary and metastatic lung tumours, since 2022 this schedule has become the preferred treatment approach. This report presents survival outcomes following SF-SBRT of 30 Gy in inoperable patients with peripheral lung tumors. Material/Methods: Patients included in this report were previously discussed at MTB. Fifty patients (50 lesions) were treated with SF-SBRT, all staged with 18FDG-PET/CT were simulated with 4D- CT to define GTV, ITV and
Digital Poster Highlight 757
Impact of adding metastatic ablative radiotherapy to Lung Consolidation in Oligometastatic NSCLC: A Randomized Controlled Study Brahma Prasad Sadangi, Amitabh Ray, Sayan Kundu, Koustav Mazumder, Bodhisattwa Dutta Radiation oncology, Chittaranjan national cancer institute, Kolkata, India
Made with FlippingBook - Share PDF online